Fakülteler / Faculties

Permanent URI for this communityhttps://hdl.handle.net/11727/1395

Browse

Filters

2017 - 20203

Settings

Author: search.filters.author.Donal, ErwanSubject: search.filters.subject.Echocardiography

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Global evaluation of echocardiography in patients with COVID-19
    (2020) Dweck, Marc R.; Bularga, Anda; Hahn, Rebecca T.; Bing, Rong; Lee, Kuan Ken; Chapman, Andrew R.; White, Audrey; Di Salvo, Giovanni; Sade, Leyla Elif; Pearce, Keith; Newby, David E.; Popescu, Bogdan A.; Donal, Erwan; Cosyns, Bernard; Edvardsen, Thor; Mills, Nicholas L.; Haugaa, Kristina; 32556199
    Aims To describe the cardiac abnormalities in patients with COVID-19 and identify the characteristics of patients who would benefit most from echocardiography. Methods and results In a prospective international survey, we captured echocardiography findings in patients with presumed or confirmed COVID-19 between 3 and 20 April 2020. Patient characteristics, indications, findings, and impact of echocardiography on management were recorded. Multivariable logistic regression identified predictors of echocardiographic abnormalities. A total of 1216 patients [62 (52-71) years, 70% male] from 69 countries across six continents were included. Overall, 667 (55%) patients had an abnormal echocardiogram. Left and right ventricular abnormalities were reported in 479 (39%) and 397 (33%) patients, respectively, with evidence of new myocardial infarction in 36 (3%), myocarditis in 35 (3%), and takotsubo cardiomyopathy in 19 (2%). Severe cardiac disease (severe ventricular dysfunction or tamponade) was observed in 182 (15%) patients. In those without pre-existing cardiac disease (n = 901), the echocardiogram was abnormal in 46%, and 13% had severe disease. Independent predictors of left and right ventricular abnormalities were distinct, including elevated natriuretic peptides [adjusted odds ratio (OR) 2.96, 95% confidence interval (CI) 1.75-5.05) and cardiac troponin (OR 1.69, 95% CI 1.13-2.53) for the former, and severity of COVID-19 symptoms (OR 3.19, 95% CI 1.73-6.10) for the latter. Echocardiography changed management in 33% of patients. Conclusion In this global survey, cardiac abnormalities were observed in half of all COVID-19 patients undergoing echocardiography. Abnormalities were often unheralded or severe, and imaging changed management in one-third of patients.
  • Thumbnail Image
    Item
    Rational and design of EuroCRT: an international observational study on multi-modality imaging and cardiac resynchronization therapy
    (2017) Sade, Elif; Donal, Erwan; Delgado, Victoria; Magne, Julien; Bucciarelli-Ducci, Chiara; Leclercq, Christophe; Cosyns, Bernard; Sitges, Marta; Edvardsen, Thor; Stankovic, Ivan; Agricola, Eustachio; Galderisi, Maurizio; Lancellotti, Patrizio; Hernandez, Alfredo; Plein, Sven; Muraru, Denisa; Schwammenthal, Ehud; Hindricks, Gerhard; Popescu, Bogdan A.; Habib, Gilbert; 28329299
    Aims Assessment of left ventricular (LV) volumes and ejection fraction (LVEF) with cardiac imaging is important in the selection of patients for cardiac resynchronization therapy (CRT). Several observational studies have explored the role of imaging-derived LV dyssynchrony parameters to predict the response to CRT, but have yielded inconsistent results, precluding the inclusion of imaging-derived LV dyssynchrony parameters in current guidelines for selection of patients for CRT. Methods The EuroCRT is a large European multicentre prospective observational study led by the European Association of Cardiovascular Imaging. We aim to explore if combing the value of cardiac magnetic resonance (CMR) and echocardiography could be beneficial for selecting heart failure patients for CRT in terms of improvement in long-term survival, clinical symptoms, LV function, and volumes. Speckle tracking echocardiography will be used to assess LV dyssynchrony and wasted cardiac work whereas myocardial scar will be assessed with late gadolinium contrast enhanced CMR. All data will be measured in core laboratories. The study will be conducted in European centres with known expertise in both CRT and multimodality cardiac imaging.
  • Thumbnail Image
    Item
    Rationale and design of the EACVI AFib Echo Europe Registry for assessing relationships of echocardiographic parameters with clinical thrombo-embolic and bleeding risk profile in non-valvular atrial fibrillation
    (2018) Sade, Leyla Elif; Galderisi, Maurizio; Donal, Erwan; Magne, Julien; Lo Iudice, Francesco; Agricola, Eustachio; Cameli, Matteo; Schwammenthal, Ehud; Cardim, Nuno; Cosyns, Bernard; Hagendorff, Andreas; Neskovic, Alexandar N.; Luis Zamorano, Jose; Lancellotti, Patrizio; Habib, Gilbert; Edvardsen, Thor; Popescu, Bogdan A.; 0000-0003-3737-8595; 29474699; AAQ-7583-2021
    The European Society of Cardiology (ESC) guidelines for management of atrial fibrillation (AF) recommend the use of CHA(2)DS(2)VASc risk score for assessment of thromboembolic (TE) risk, whereas the stratification of bleeding risk should be obtained by HAS-Bleed to balance the most appropriate anticoagulation (OAC) therapy. However, men with CHA(2)DS(2)VASc score=1 and women with CHA(2)DS(2)VASc=2, who are at intermediate TE risk, represent a grey zone where guidelines do not provide a definite OAC indication. Accordingly, implementation of risk stratification with echocardiography could be extremely useful. Both prospective and cross-sectional studies on transthoracic echocardiography (TTE) prediction of TE events and studies utilizing transoesophageal echocardiographic parameters as surrogate markers of TE events makes sustainable the hypothesis that echocardiography could improve TE prediction in non-valvular AF. Moreover, considering the close association of AF and stroke, all echo-Doppler parameters that have shown to predict AF onset and recurrence could be useful also to predict TE events in this clinical setting. Accordingly, EACVI AFib Echo Europe Registry has been designed as an observational, cross-sectional study, with the aim of evaluating: (i) left atrial (LA) size and function together with left ventricular geometry, systolic and diastolic functions in paroxysmal, persistent, and permanent AF; (ii) relationships of structural/ functional parameters with clinical TE and bleeding risk profile. By the AFib Echo Europe Registry, we expect to collect data on echocardiographic phenotype of patients with AF. The large data set accumulated will be useful to test the level of agreement of different echocardiographic measurements with the available risk scores.